Results 11 to 20 of about 331,612 (290)
A small interfering RNA (siRNA) database for SARS-CoV-2
Scientific Reports, 2021 Coronavirus disease 2019 (COVID-19) rapidly transformed into a global pandemic, for which a demand for developing antivirals capable of targeting the SARS-CoV-2 RNA genome and blocking the activity of its genes has emerged.
Inácio Gomes Medeiros +5 more
doaj +1 more source
Therapeutic opportunities of small interfering RNA [PDF]
Fundamental & Clinical Pharmacology, 2009 AbstractFormation of small interfering RNA (siRNA) occurs in two steps involving binding of the RNA nucleases to a large double‐stranded RNA (dsRNA) and its cleavage into fragments called siRNA. In the second step, these siRNAs join a multinuclease complex, which degrades the homologous single‐stranded mRNAs.
Shraddha V. Bhadada +3 more
openaire +3 more sources
Small interfering RNAs in the management of human osteoporosis
British Medical Bulletin, 2023 Abstract Background Osteoporosis results in reduced bone mass and consequent bone fragility. Small interfering RNAs (siRNAs) can be used for therapeutic purposes, as molecular targets or as useful markers to test new therapies. Sources of data
Giuseppe Gargano +4 more
openaire +3 more sources
Endogenous small interfering RNAs in animals [PDF]
Nature Reviews Molecular Cell Biology, 2008 Until recently, only nematodes among animals had a well-defined endogenous small interfering RNA (endo-siRNA) pathway. This has changed dramatically with the recent discovery of diverse intramolecular and intermolecular substrates that generate endo-siRNAs in Drosophila melanogaster and mice.
Eric C. Lai, Katsutomo Okamura
openaire +3 more sources
Small Interfering RNA in Colorectal Cancer Liver Metastasis Therapy
Technology in Cancer Research & Treatment, 2022 Colorectal cancer (CRC) is associated with numerous genetic disorders and cellular abnormalities, and liver metastasis is a common health concern in patients with CRC.
Junlin Xie MM, Shubin Wang MD
doaj +1 more source
Medicinal Chemistry of Oligonucleotide Drugs - Milestones of the Past and Visions for the Future
CHIMIA, 2022 The oligonucleotide therapeutics field has blossomed in recent years, with thirteen approved drugs today and the promise of accelerated growth in coming years.
Jonathan Hall +7 more
doaj +1 more source
Updates in Small Interfering RNA for the Treatment of Dyslipidemias
Current Atherosclerosis Reports, 2023 Abstract Purpose of Review Atherosclerotic cardiovascular disease (ASCVD) is still the leading cause of death worldwide. Despite excellent pharmacological approaches, clinical registries consistently show that many people with dyslipidemia do not achieve optimal management, and many of them are treated with low-intensity
Carugo, S. +5 more
openaire +2 more sources
Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib
Haematologica, 2010 Background Selective inhibition of the BCR-ABL tyrosine kinase by RNA interference has been demonstrated in leukemic cells. We, therefore, evaluated specific BCR-ABL small interfering RNA silencing in BCR-ABL-positive cell lines, including those ...
Michael Koldehoff +3 more
doaj +1 more source
An influenza virus-inspired polymer system for the timed release of siRNA [PDF]
, 2013 Small interfering RNA silences specific genes by interfering with mRNA translation, and acts to modulate or inhibit specific biological pathways; a therapy that holds great promise in the cure of many diseases. However, the naked small interfering RNA is
A Fire +37 more
core +2 more sources
Traffic into silence: endomembranes and post-transcriptional RNA silencing. [PDF]
, 2014 microRNAs (miRNAs) and small interfering RNAs (siRNAs) are small RNAs that repress gene expression at the post-transcriptional level in plants and animals. Small RNAs guide Argonaute-containing RNA-induced silencing complexes to target RNAs in a sequence-
Chen, Xuemei +2 more
core +3 more sources